MedTrace Logo

Osteopathic Manipulative Treatment and Migraine Headaches

NCT04976985 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2021-08-03

No results posted yet for this study

Summary

In this study the investigators hypothesize, that Osteopathic Manipulative Therapy (OMT) will reduce migraine disability and severity scores when compared to standard of care including prophylactic pharmacological agents with treatment over 12 week time frame. The investigators aim to decrease severity and disability of migraine by utilizing Osteopathic Manipulative Therapy. This would ultimately reduce the utilization of office or emergency department visits, decrease the large economic burden the United States faces for migraine patients as well as improve quality of life for the 3 million chronic migraine patients.

Conditions

  • Chronic Migraine
  • Migraine Disorders
  • Headache Disorders
  • Headache, Migraine

Interventions

PROCEDURE

Osteopathic Manipulative Therapy (OMT)

Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic physicians receive special training in the musculoskeletal system to detect somatic dysfunction. Osteopathic physicians then move a patient's muscles and joints using techniques that include stretching, gentle pressure and resistance to improve muscle tonicity, treat structural abnormalities, relieve joint restriction, and decrease activation of the pain proprioception pathway. OMT Standardized Protocol A: 1. Occipital- Alanto release 2. Muscle energy and soft tissue to mid trapezius muscle 3. Muscle energy to cervical spine in all three planes of flexion/extension, rotation and side bending 4. Screening for tender points of C2-C6 at transverse and spinous processes and treatment with counterstain if tender point identified 5. Soft tissue to cervical paraspinal muscles 6. Myo-fascial release of frontal forehead 7. CV4 cranial technique

OTHER

Standard of care

Receiving standard of care for migraine headaches with pharmacological medications, with no more than two prophylactic medications during the study period. Participants may also take abortive migraine medications.

Sponsors & Collaborators

  • St. Luke's Hospital, Pennsylvania

    lead OTHER

Principal Investigators

  • Abby Rhoads, DO · St. Luke's Hospital and Health Network, Pennsylvania

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-02
Primary Completion
2022-03-30
Completion
2022-03-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04976985 on ClinicalTrials.gov